Starpharma Holdings Ltd has released a press release.
SPL7013 shows potent antiviral activity in RSV
Filed with ASX ·
6ix hasn’t read this filing yet.
Starpharma Holdings Limited on 6ix
In the deck
Earlier from Starpharma
- Completion of Placement and SPP raises $48.9M in total
- Starpharma receives $5.7M R&D tax incentive refund
- Share Purchase Plan offer document
- Starpharma completes oversubscribed A$45M placement
- SPL7013 COVID-19 nasal spray virucidal against SARS-CoV-2
Later from Starpharma
- VIRALEZE COVID-19 nasal spray to be ready for market Q1CY21
- VIRALEZE COVID-19 nasal spray study to commence in January
- Change in substantial holding
- AZD0466 clinical DEP program global expansion
- Starpharma signs DEP ADC Research Agreement with MSD
Follow Starpharma into a list and get an email when it puts out news.
Follow Starpharma